Company intelligence / Profile preview

SOMAVAC

Memphis, Tennessee, United Statessomavac.com ↗

Ownership: Private
Employees: ~8
Development stage: Commercial

Overview

The SOMAVAC® SVS device has achieved FDA clearance and commercial launch. Clinical data indicate it enables removal of surgical drains up to 30% sooner than standard of care, reducing complications such as infection and reoperation. Over 1,200 units have been sold in initial pilot markets with ongoing clinical pilots expanding across five U.S. cities as of early 2025.

Therapeutic areas: OncologyCardiovascularOther
Modalities: DeviceNegative pressure therapy system
Industry: Therapeutic Medical Devices

Partnerships

A Fitting Place (retail partner for distribution to breast cancer patients)

Beyond the preview

Go deeper on SOMAVAC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SOMAVAC.

Explore the full profile